Alpha-gal Syndrome and Blood Transfusions: A Newly Recognized Risk

A New Study Raises Important Questions About Transfusion Safety in Patients with Alpha-gal Syndrome

For years, Alpha-gal Syndrome has primarily been discussed as a food allergy triggered by mammalian meat.

A newly published study suggests there may be another important conversation healthcare providers need to have: blood transfusions.

Researchers recently described two patients with known Alpha-gal Syndrome who experienced severe allergic transfusion reactions after receiving blood products containing plasma from blood groups associated with alpha-gal-related risk. Both patients required emergency treatment for reactions consistent with anaphylaxis. 

Perhaps even more concerning, both patients already had Alpha-gal Syndrome documented in their medical records before the transfusions occurred. Yet neither diagnosis was recognized as a transfusion risk factor when blood products were selected. 

What Did the Researchers Find?

The study examined a phenomenon now being called: Transfusion-Related Alpha-gal Syndrome (TRAGS)

Researchers believe that certain plasma-containing blood products may trigger allergic reactions in some patients who have already developed Alpha-gal Syndrome. 

To better understand whether this was an isolated issue, investigators reviewed five years of allergic transfusion reactions at a major medical center in Tennessee.

Among 50 qualifying allergic transfusion reactions:

• 13 were severe or anaphylactic.

• Alpha-gal testing was performed in none of the cases.

• No patient had Alpha-gal Syndrome documented as a possible cause of the reaction. 

The authors described this as a significant diagnostic gap.

Awareness Is Not the Same as Recognition

One of the most striking findings was that Alpha-gal Syndrome was already known in both of the newly reported patients.

The diagnosis was in the chart.

The diagnosis was documented.

Yet the diagnosis was not incorporated into transfusion decision-making. 

This finding echoes a theme repeatedly reported by participants in the TickBiteData survey population: Awareness does not always translate into recognition.

Patients frequently report that healthcare providers have heard of Alpha-gal Syndrome but may not fully understand how it affects medications, medical procedures, implanted materials, vaccines, biologics, or now potentially blood transfusions.

Why This Matters

The study does not suggest that every patient with Alpha-gal Syndrome is at risk during transfusion.

It does not prove that Alpha-gal Syndrome itself can be transmitted through blood products.

However, it does suggest that Alpha-gal Syndrome may represent an under-recognized risk factor when selecting blood products for some patients. 

The authors argue that healthcare systems in tick-endemic regions should consider:

• Asking about Alpha-gal Syndrome before transfusion.

• Incorporating AGS into transfusion risk assessments.

• Evaluating Alpha-gal as a potential cause of unexplained allergic transfusion reactions.

• Developing electronic medical record alerts for known AGS patients. 

A Broader Lesson

Perhaps the most important lesson from this study extends beyond blood transfusions. The paper highlights a challenge many patients know well: A diagnosis can exist in a medical record and still fail to influence care.

The researchers found that Alpha-gal Syndrome was not missing from the chart. It was missing from the clinical decision-making process. 

That distinction matters.

Because awareness alone does not improve outcomes.

Recognition does.

What Questions Remain?

The study raises several important questions:

• How common are Alpha-gal-related transfusion reactions?

• Are some blood products higher risk than others?

• Should Alpha-gal screening become part of transfusion protocols in endemic regions?

• How many allergic transfusion reactions currently classified as "idiopathic" may actually involve Alpha-gal sensitization?

• What other healthcare settings may be overlooking Alpha-gal-related risks?

Future research will be needed to answer these questions.

But one thing is already clear: Alpha-gal Syndrome may be relevant in more healthcare settings than many providers realize.

Transparency Matters

The goal of patient-reported data and clinical research is not simply to raise awareness. It is to identify gaps, improve recognition, and ultimately improve outcomes for patients and families.

This study adds to a growing body of evidence suggesting that Alpha-gal Syndrome may affect far more than food choices alone.

And for many patients, that broader clinical picture is already familiar.